Several studies have focused on PCa patients with a “normal” PSA level (< 4 ng/ml), who should have better disease characteristics and better outcomes, but were discovered with some biologically aggressive characteristics [9–14]. This evidence concerns the gene KLK3 and posterior cortical atrophy.